Cagrilintide + Semaglutide

This blend is positioned as a ‘dual‑satiety’ strategy by combining an amylin analog with a GLP‑1 receptor agonist. Cagrilintide is described as a long‑acting amylin analog that reduces appetite through central satiety pathways; amylin signaling is also associated with delayed gastric emptying and satiety signaling via brainstem circuits such as the area postrema. GLP‑1S (a semaglutide‑type GLP‑1 receptor agonist) contributes complementary effects: it increases glucose‑dependent insulin secretion, suppresses glucagon, slows gastric emptying, and adds central appetite suppression. The rationale for the combination (referred to as a CagriSema‑style approach) is that overlapping but non‑identical mechanisms can produce greater weight‑loss efficacy than either pathway alone, as reported in clinical trial outcomes for co‑administration. Side‑effect expectations follow the GLP‑1/amylin profile: primarily gastrointestinal intolerance (nausea, vomiting, diarrhea), improved by gradual titration, plus mild, transient injection‑site reactions.